{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dutra-Tavares AC"],"funding":["Conselho Nacional de Desenvolvimento Científico e Tecnológico","Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro"],"pagination":["e0257986"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8480744"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(9)"],"pubmed_abstract":["The first symptoms of schizophrenia (SCHZ) are usually observed during adolescence, a developmental period during which first exposure to psychoactive drugs also occurs. These epidemiological findings point to adolescence as critical for nicotine addiction and SCHZ comorbidity, however it is not clear whether exposure to nicotine during this period has a detrimental impact on the development of SCHZ symptoms since there is a lack of studies that investigate the interactions between these conditions during this period of development. To elucidate the impact of a short course of nicotine exposure across the spectrum of SCHZ-like symptoms, we used a phencyclidine-induced adolescent mice model of SCHZ (2.5mg/Kg, s.c., daily, postnatal day (PN) 38-PN52; 10mg/Kg on PN53), combined with an establ"],"journal":["PloS one"],"pubmed_title":["Does nicotine exposure during adolescence modify the course of schizophrenia-like symptoms? Behavioral analysis in a phencyclidine-induced mice model."],"pmcid":["PMC8480744"],"funding_grant_id":["finance code 001","304332/2016-0","SEI-260003/001135/2020","141270/2019-5","E-26/202.792/2017","E-26/202.266/2018","132524/2019-8","E-26/010.100961/2018"],"pubmed_authors":["Dutra-Tavares AC","Manhaes AC","Maia JG","Ribeiro-Carvalho A","Abreu-Villaca Y","Couto LA","Semeao KA","Filgueiras CC"],"additional_accession":[]},"is_claimable":false,"name":"Does nicotine exposure during adolescence modify the course of schizophrenia-like symptoms? Behavioral analysis in a phencyclidine-induced mice model.","description":"The first symptoms of schizophrenia (SCHZ) are usually observed during adolescence, a developmental period during which first exposure to psychoactive drugs also occurs. These epidemiological findings point to adolescence as critical for nicotine addiction and SCHZ comorbidity, however it is not clear whether exposure to nicotine during this period has a detrimental impact on the development of SCHZ symptoms since there is a lack of studies that investigate the interactions between these conditions during this period of development. To elucidate the impact of a short course of nicotine exposure across the spectrum of SCHZ-like symptoms, we used a phencyclidine-induced adolescent mice model of SCHZ (2.5mg/Kg, s.c., daily, postnatal day (PN) 38-PN52; 10mg/Kg on PN53), combined with an establ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-06-01T01:29:02.045Z","creation":"2022-02-11T11:29:52.478Z"},"accession":"S-EPMC8480744","cross_references":{"pubmed":["34587208"],"doi":["10.1371/journal.pone.0257986"]}}